← Back to Search

Other

RG7774 for Diabetic Retinopathy (CANBERRA Trial)

Phase 2
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to 52 weeks
Awards & highlights

CANBERRA Trial Summary

This trial is testing a new drug to see if it's safe and effective at treating a certain kind of diabetes-related eye disease.

Eligible Conditions
  • Diabetic Retinopathy

CANBERRA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants with Adverse Events (AEs)
Proportion of Participants with >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) from Baseline at Week 36 Measured in the Study Eye
Secondary outcome measures
Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Percentage of Participants with Anterior Segment Neovascularization (ASNV), new Proliferative Diabetic Retinopathy (PDR), new Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention

CANBERRA Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group CExperimental Treatment1 Intervention
Participants will receive a high oral dose of RG7774 QD
Group II: Group BExperimental Treatment1 Intervention
Participants will receive a low oral dose of RG7774 QD
Group III: Group APlacebo Group1 Intervention
Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RG7774
2020
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,430 Previous Clinical Trials
1,089,318 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
174 Patients Enrolled for Diabetic Retinopathy
Clinical TrialsStudy DirectorHoffmann-La Roche
2,201 Previous Clinical Trials
888,628 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
174 Patients Enrolled for Diabetic Retinopathy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When might the FDA approve RG7774?

"While there is some evidence from Phase 2 trials that RG7774 is safe, Power's team has only given it a score of 2 because none of the data collected supports efficacy."

Answered by AI

Are there still opportunities to participate in this research?

"The website clinicaltrials.gov specifies that this trial is currently enrolling patients. This research project was originally published on June 5th, 2020 and was last updated November 10th, 2022. The study needs a total of 135 participants from 30 different locations."

Answered by AI

In how many different places is this research being conducted?

"30 different medical centres are running this trial, for example Strategic Clinical Research Group, LLC in Germantown, Retina Research Center in Willow Park, and Austin Clinical Research, Inc in Austin."

Answered by AI

Who else is applying?

What state do they live in?
California
Florida
Texas
Other
How old are they?
18 - 65
What site did they apply to?
Global Research Management
Florida Eye Associates
Retina Consultants of Texas
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

i like trial's especially if i get the stuff vs. placebo.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
2020. "A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04265261.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top